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ABSTRACT
Objectives To evaluate an implementation programme of 
a community pharmacy medication review with follow- up 
(MRF) service using a hybrid effectiveness- implementation 
study design, and to compare the clinical and humanistic 
outcomes with those in a previously conducted cluster 
randomised controlled trial (cRCT).
Setting Community pharmacies in Spain.
Participants 135 community pharmacies and 222 
pharmacists providing MRF to polymedicated patients 
aged 65 or over.
Intervention The intervention was an implementation 
programme for the MRF service. A national level group was 
established, mirrored with a provincial level group. A series 
of interventions were defined (1) to engage pharmacy 
owners with the implementation model and (2) to provide 
training to pharmacists consisting of clinical case studies, 
process of MRF, communication skills and data collection 
methods and (3) practice change facilitators.
Primary and secondary outcome measures The 
primary outcomes for the implementation programme 
were progress, reach, fidelity and integration. The 
secondary outcomes were number of medications, 
non- controlled health problems, emergency visits, 
hospitalisations and health- related quality of life, which 
were compared with a previous 6- month cluster RCT.
Results 55% of pharmacies reached the implementation 
phase and 35.6% remained in the testing phase at 12 
months. A reach of 89.3% (n=844) was achieved. Fidelity 
average score was 8.45 (min: 6.2, max: 9.3) out of 10. The 
integration mean score was 3.39 (SD: 0.72) out of 5. MRF 
service outcomes were similar to the cluster RCT study; 
however, the magnitude of the outcomes was delayed.
Conclusions The implementation of pharmacy services is 
a complex multifactorial process, conditioned by numerous 
implementation factors. In the absence of remuneration, 
the implementation of the MRF service is a slow process, 
taking at least 12 months to complete.
Trial registration number CGFTRA-2017-01.
BACKGROUND
Over the last two decades many research 
programmes have evaluated professional 
pharmacy services delivered from commu-
nity pharmacies. Systematic reviews and 
meta- analysis are being published proving 
or attempting to evaluate the clinical and 
humanistic impact on patients and the 
economic benefits to healthcare systems.1 2 As 
new professional pharmacy services are being 
designed, randomised controlled trials 
(RCTs) continue to be undertaken in 
controlled environments.3 However, much 
less attention has been paid to the devel-
opment and evaluation of implementation 
programmes associated with the widespread 
adoption and scaling up of these services. 
Strengths and limitations of this study
 ► Community pharmacist- led medication review with 
follow- up (MRF) has the objective of improving 
medication management, managing chronic health 
problems and improving patients’ quality of life.
 ► MRF service has previously been shown to be clin-
ically effective and cost- effective in cluster ran-
domised controlled trials.
 ► The impact of a multilevel implementation pro-
gramme was evaluated in 135 sites, with a 55% im-
plementation success with high reach, fidelity and 
integration scores.
 ► Service benefits were similar to those previously ob-
tained in a cluster randomised controlled trial; how-
ever, the magnitude of the outcomes was delayed 
from 6 to 12 months.
 ► A limitation of the study was the self- reporting na-
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Nevertheless, national and provincial governments have 
incorporated pharmacy services as part of their health-
care policies. In many countries such as England, Canada, 
Australia and the USA, community pharmacies are being 
remunerated for a range of medication management and 
disease- related programmes and services.4–7
Implementation of innovations, new practices and 
services, which is often unsuccessful, is a complex and 
long- term process that requires holistic approaches 
tailored at multiple domains. The lack of translation of 
evidence to practice phenomenon is common across 
many different disciplines ranging from agriculture, 
health, education and teaching, to pharmacy, among 
others.8 Successful implementation requires the use of 
models and frameworks that provide a structured and 
sound theoretical approach to implementation processes 
and outcomes.9 Current knowledge on implementation 
of innovations in healthcare shows that an implementa-
tion framework is crucial to successful implementation 
and long- term sustainability. A commonly used frame-
work, the Consolidated Framework for Implementation 
Research by Damschroder et al,10 was adapted by Moullin 
et al so as to be pharmacy discipline- specific. An evalu-
ation framework was also proposed by Moullin et al to 
measure the effect of implementation programmes on 
professional pharmacy services.11
Community pharmacist- led medication review with 
follow- up (MRF), prioritised as a national pharmacy 
service by Spanish pharmaceutical organisations, is 
a service with the objective of improving medication 
management, managing chronic health problems and 
improving patients’ quality of life.12 MRF was designed 
and developed through consensus by a body of organ-
isations which included universities and professional 
organisations and met under the auspices of the General 
Council of Colleges of Pharmacy.13 MRF can be classified 
as a type 3 or advanced medication review service using 
the Pharmaceutical Care Network definition of medi-
cation review services.14 A study on the impact of MRF 
has shown positive clinical, economic and humanistic 
outcomes.15 In 2019 a systematic review conducted by 
the National Institute for Health and Care Excellence in 
the UK on the cost- effectiveness of advanced pharmacy 
services was published confirming these findings.16
Due to MRF’s proven efficacy, the next phase of the 
research was to design, develop and evaluate an imple-
mentation programme which would be used to scale up 
to a national level. Some dissemination of MRF services 
had transpired during the national process of prioriti-
sation of services. The prospect of patient benefits and 
increased professional satisfaction has not been sufficient 
to drive implementation nor had passive diffusion strate-
gies such as training.17–19 There was also a lack of direct 
financial incentives to adopt the practice, an important 
factor particularly in the community pharmacy business 
setting.20 Importantly there is a high probability that wide-
spread implementation had not been achieved because 
a comprehensive multilevel programme has not been 
used.21–23 Alongside using an implementation model, the 
literature suggests that combinations and more active 
strategies need to be employed particularly if the clin-
ical, economic and humanistic benefits shown during its 
impact research phase are to be translated to the target 
population.18 The objective of the study was to evaluate 
the impact of an implementation programme for MRF in 
community pharmacies and to compare the clinical and 
humanistic outcomes with those achieved in the impact 
research phase.
METHODS
The ‘Standards for Reporting Implementation Studies’ 
checklist with the accompanying explanation and elab-
oration documentation and guidelines were used in 
preparing this paper.24 However, we did not have suffi-
cient data to report on item 8, that is, the ‘full character-
istics of the target sites’, as there were 135 different sites, 
and on items 13 and 20, ‘economics’ of the standards.
Study design and context
A hybrid effectiveness- implementation design was used.25 
The complete methodology of both the impact study 
and the implementation programme has been previously 
described.26 27 The implementation programme study was 
undertaken during 12 months in 2015–2016.
MRF intervention
The MRF service was the intervention to be imple-
mented. MRF is a professional pharmacy service whose 
ultimate objective is to detect drug- related problems in 
order to prevent and solve negative outcomes associated 
with medications. The service is delivered according to 
the following phases: (1) patient recruitment; (2) first 
patient interview (with the objective of retrieving relevant 
clinical and medicines information); (3) comprehensive 
medication review (where drug- related problems and 
negative outcomes associated with medications are iden-
tified); (4) delivery of a care plan agreed with the patient 
and other healthcare professionals (targeted at the prob-
lems identified in phase (3)); and (5) follow- up visits (to 
monitor the outcomes achieved and assess potential new 
drug- related problems and negative outcomes associated 
with medications).
During this study community pharmacists did not have 
access to the formal clinical patient record. However, 
during the interview the pharmacists solicited hard copies 
of reports, which patients have as part of normal medical 
practice in Spain. These reports included diagnostic and 
analytical laboratory results. There were a number of 
ways in which the pharmacist evaluated the control of the 
health condition: data from the documentation provided 
by the patient, symptoms reported by the patient, in rele-
vant cases measuring blood pressure and other tests, and 
from responses to disease- specific questionnaires. Using 
this clinical information, the pharmacist applied his/her 
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At baseline patients were asked to provide the number 
of hospital admissions and emergency visits undertaken 
in the previous 6 months. At subsequent visits they were 
asked to report on the number of visits undertaken during 
the intervening time. In the case of hospitalisations, the 
patient unique identifier was used and the information 
was validated through hospital records as well as accessing 
the Diagnosis Related Group. In a previous work15 similar 
data were correlated with the influence of drug- related 
problems on the hospitalisation rate. In an additional 
study these data were also analysed with the opinion 
of three internal specialists having obtained a good 
correlation.28
Setting and study population
The service was to be implemented in community phar-
macies in 11 Spanish provinces (A Coruña, Albacete, 
Ciudad Real, Córdoba, Gipuzkoa, Granada, Guadala-
jara, Huelva, Las Palmas, Santa Cruz de Tenerife and 
Valencia). Community pharmacy owners were offered to 
participate in the study and a maximum of 14 pharmacies 
were randomly selected in each province, according to 
the following criteria: (1) pharmacy with patients aged 
65 or over and (2) pharmacy owner available to attend 
an initial training and willing to implement the service. 
Community pharmacists working in the participating 
community pharmacies offered eligible patients to enter 
the study. Eligible patients were aged 65 or over using five 
or more chronic medications.
Implementation framework
The Framework for the Implementation of Services in 
Pharmacy model,11 which had been adapted from the 
consolidated framework by Damschroder et al,10 was 
used as part of the implementation programme. In this 
model the progress of the service implementation passes 
through different phases: exploration, preparation, 
testing and implementation. For this study each phase was 
operationally defined as follows: exploration: the number 
of pharmacies (a pharmacist can only own one pharmacy 
in Spain) who had decided to enrol in the programme; 
preparation: the number of pharmacies represented by 
pharmacists attending the face- to- face training: and the 
testing phase, which started when a pharmacy had at least 
one patient receiving the service with at least one pharma-
cist intervention (with the patient or with the physician). 
Finally, the implementation phase was reached when 
there were at least seven patients receiving the service. 
This number of patients was based on the results of the 
impact study which indicated that a pharmacy without 
extra resources, that is, without payment, could maintain 
this number of patients.
Implementation strategy
At the national level an implementation group with senior 
personnel provided high- level political and management 
leadership. At the meso level, this was mirrored with the 
establishment of a provincial- level college of pharmacy 
group with the same objectives as the national group. For 
the meso level a series of interventions were designed. 
Pharmacy owners were requested to attend a 4- hour 
information session which included the descriptions of 
international modes of professional services, the imple-
mentation model, and the professional and business 
advantages of implementing the MRF service. Over 3 
days, face- to- face training for service providers consisted 
of clinical case studies, process of MRF, communica-
tion skills and data collection methods. Third, practice 
change facilitators (PCF) were employed by local colleges 
of pharmacy as part of the implementation programme. 
These PCFs were trained for 5 days and were educated on 
the implementation model, motivational and communi-
cation skills, and to identify barriers and facilitators for 
the practice change in situ in the pharmacy. PCFs were 
provided with a list of 43 implementation factors previ-
ously identified from the literature and from the impact 
study that were relevant to the implementation of MRF 
services (see online supplemental file 1). An observation 
guide was designed to allow PCFs to identify, systemati-
cally and individually in each pharmacy, the determi-
nants, that is, barriers or facilitators and their causes. The 
PCF also quality- controlled data collection. Participant 
observation, through direct observation, collective discus-
sion and document analysis were conducted during these 
visits in order to gain an understanding of relevant imple-
mentation factors within the pharmacy. Post visit, the PCF 
analysed the data collected. An electronic documentation 
programme was provided where all these activities could 
be formally documented and analysed by PCFs and the 
research team. PCFs visited the pharmacy monthly and 
also provided telephone and email support. The research 
team held regular Skype meetings with PCFs to assist in 
the discharge of their duties.
Evaluation of implementation process and outcomes
The Moullin et al11 evaluative framework (figure 1) was 
used to assess the progress of the implementation. The 
implementation outcomes measured were progress of 
the implementation, that is, stages, rate and reach. The 
‘climate indicators’ are reported in a separate paper. 
The validated questionnaires published in English by 
Moullin et al29 were used to measure fidelity and integra-
tion. The fidelity and integration questionnaires were to 
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be completed by each pharmacist provider of the MRF 
service.
Evaluation of service outcomes
Finally, clinical and humanistic outcomes similar to 
those of the impact research phase were measured. A 
medication history was undertaken by the pharmacist as 
part of the MRF service and the number of medications 
extracted from these interviews. Each patient’s clinical 
history was also taken and the patient’s results compared 
with approved clinical guidelines to determine whether 
the underlying chronic disease was controlled or not. 
The number of emergency visits and hospitalisations was 
provided through a patient interview during the 6 months 
prior to receiving the service and at two timepoints (6 
and 12 months) during the service. For perceived health- 
related quality of life, European Quality of Life Scale- 5D 
and Visual Analogue Scale were used.30
Data analysis
To describe quantitative variables, mean and SD were 
used. Student’s t- test was used to test independent vari-
ables. To describe qualitative data, frequency measures 
(percentages) were used. χ2 and Fisher’s tests were used 
to analyse the relationship between categorical variables.
Consent to participate
Written consent was obtained from all participants.
Patient and public involvement
Patients or the public were not involved in the design, 
or conduct, or reporting, or dissemination plans of our 
research.
RESULTS
A total of 246 pharmacies responded to the request for 
information on the project, with 155 pharmacies from 11 
provinces accepting to participate in the implementation 
programme. Due to restriction of human resources 135 
were randomly selected and participated in the imple-
mentation programme. Training sessions were attended 
by pharmacy owners and pharmacists from these 
pharmacies.
Progress of implementation
Within the first month 63% (n=85) of pharmacies had 
undertaken an intervention with either a medical practi-
tioner and/or a patient and were thus classified to be in 
the testing phase, while 2.2% (n=3) had moved to imple-
mentation of the service, meeting the full quota of seven 
patients. Between the third and fourth months, the largest 
percentage (76.3%, 103) of pharmacies had moved to 
testing phase, with 13% (n=18) moving to implemen-
tation phase. Only seven pharmacies remained in the 
preparation phase by month 5 (figure 2). The percentage 
of pharmacies in the implementation phase steadily rose 
to a maximum of 55% of the original 135 reaching this 
phase, with 35.6% (n=48) remaining in the testing phase 
12 months after the commencement of the programme. 
The first dropouts, three pharmacies, occurred in month 
5, and after 1 year of the programme there were a total of 
13 dropouts (3.4%).
Reach in implementation programme
As 135 participating pharmacies and at least seven 
patients per pharmacy were expected, 945 was the target 
patient reach. At the end of the study, a reach of 89.3% 
(n=844) was achieved. After the first month of the study, 
210 patients (approximately 25%) were recruited, with 
50% recruitment within 5 months of commencing the 
programme and 75% within 7 months (figure 3).
Fidelity to the MRF service
There were 222 pharmacist providers in the study (1.64 
per pharmacy). A total of 161 questionnaires on fidelity 
were completed by participating pharmacist providers, 
resulting in a response rate of 72.5%. A total of 145 ques-
tionnaires were included in the final analysis (90.0%), 
with 16 (9.9%) discarded due to missing data. The overall 
average score of the items on the questionnaire was 
8.45 (min: 6.17, max: 9.33) (table 1). The stage with the 
highest score was ‘general service’ aspects and the lowest 
was ‘service offer’. The validated questionnaire in Spanish 
is provided in online supplemental file 2.
MRF integration
From the 222 participating pharmacist providers, 108 
questionnaires were completed, resulting in a response 
rate of 48.6%. The average score obtained for the total 
number of items was 3.39 (SD: 0.72) out of 5 (table 2). 
The best rated dimension was resources, with 4.39±0.63, 
and the worst rate was evaluation, with 2.99±0.11, with 
item 31 (‘The operation of the Service is evaluated peri-
odically’, 2.87±1.22) performing the worst. The validated 
questionnaire in Spanish is provided in online supple-
mental file 3.
Service outcomes
The differences in the sample characteristics and health 
outcomes for the impact study undertaken for 6 months 
and the implementation programme at 6 and 12 months 
Figure 2 Progress of pharmacies through the different 
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are shown in tables 3–8. Six hundred and eight patients 
were recruited and followed for 6 months in the imple-
mentation programme. Of these patients, data for the 
12- month point were available only for 176 patients as the 
fieldwork ended 12 months from initial commencement 
of the programme.
On comparing the baseline patient characteristics for 
patients followed for 6 months, there were significant 
differences in the mean number of medications (9.05 
(3.0) vs 7.74 (2.5)) and the number of health problems 
(5.98 (2.0) vs 4.96 (1.8)), both of which were higher for 
recruited patients in the implementation programme. For 
patients followed for 12 months in the implementation 
programme, in addition to these significant differences, 
differences were also found in the mean age of patients 
approximately 2 years (73.4 (5.7) vs 75.3 (6.5)) (table 3).
Even though the baseline number of medications 
was statistically significantly higher in the sample for 
the implementation programme (9.05 (3.0)) and (9.38 
(3.1)) than the impact study population (7.74 (2.5)), the 
pattern of decrease in the number of medications in the 
implementation programme did not become significant 
until the 12- month point (table 4).
At baseline, there were significant differences in the 
number of non- controlled health problems between 
the three samples. The decrease at 6 months, although 
significantly different, was lower in the implementation 
programme than in the impact study (−57.5% vs −38.1%). 
At 12 months, the percentage decrease was of similar 
magnitude (−57.5% vs −52.2%) between the impact study 
and at 12 months for the implementation programme 
(table 5).
The percentage decrease in emergency visits at 6 
months, even accounting for baseline differences, was 
lower in the implementation programme than in the 
impact study (−49.1% vs −43.0%). At 12- month point, the 
percentage decrease was greater by about 10% than the 
impact study (−49.1% vs −56.8%) (table 6).
There were no significant differences at baseline for the 
reported number and/or percentage of hospitalisations 
in the three samples (table 7). Significant differences 
were seen at 6 and 12 months in the decrease in hospital-
isations, reaching a decrease of −63.2% in hospitalisations 
in the implementation programme at 12 months.
There were statistical differences in changes from base-
line quality of life in all three samples, with an increase 
of 6.74 (18.7) in the 12- month point of the implementa-
tion programme. At the 6- month time, the change in the 
impact study was higher than that of the implementation 
programme (5.51 (15.3) vs 2.89 (17.0)) (table 8).
DISCUSSION
This study in community pharmacies provided the results 
of the implementation process and the evolution of phar-
macies through the different stages of an implementation 
model for the MRF service. In community pharmacies, 
the application of a theoretical implementation model 
following a rigorous hybrid effectiveness design is novel. 
This approach allowed the analysis of the effectiveness of 
the implementation programme in a structured holistic 
way, with the aim of not only evaluating and measuring 
implementation effectiveness but importantly the clinical 
benefits previously identified in the impact study on the 
target population. At the same time, it allowed the identi-
fication of areas for improvement in the future, including 
the type of training provided at different levels and the 
length of time required for the scaling- up programme.
By the end of the 12- month programme, just over half 
of the original 135 pharmacies reached the predefined 
implementation stage. Over a third of the pharmacies 
remained in the testing phase, highlighting the need 
for both a longer scaling- up period and the necessity to 
Figure 3 Reach achieved in the implementation 
programme.
Table 1 Fidelity after 12 months of MRF service provision
Fidelity at each stage of the MRF service Mean SD
Service offer 7.95 1.13
First patient interview 8.62 0.42
Determination of patient’s current health 
status
8.74 0.19
Case study phase 8.60 0.17
Evaluation phase 8.87 0.36
Intervention phase 8.37 0.42
Successive interviews and evaluation of 
outcomes
8.19 0.10
General service aspects 8.88 0.39
MRF, medication review with follow- up.
Table 2 Integration achieved at 12 months by the 
implementation programme
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review the support systems used. Reach is an important 
variable that is critical to measure in order to ensure 
testing of the universality of the programme in target 
populations. In many ways it determines the success of 
the implementation programme. Most participating 
pharmacies (80%) recruited at least a patient within 
the service after 2 months of the programme, indicating 
that initial uptake was not an issue. However, the overall 
reach achieved was 90%, indicating the variability of 
recruitment by pharmacies. An average of 7.5 patients 
were reached per pharmacy, indicating the success of the 
preparation intervention. Service delivery, that is, recruit-
ment, between months 0 and 3 accounted for a third 
of the patients participating, and by the end of month 
6 two- thirds of the patients were receiving the medica-
tion review programme with follow- up. This speed of 
recruitment may be due to the motivation with which the 
majority of the pharmacist providers adopted the service. 
Their wish to differentiate and professionalise the phar-
macy has been identified as a relevant facilitator for the 
implementation of new pharmacy service.31 While it is 
valid to suggest that this motivation is essential to imple-
ment any complex service as the MRF service, motivation 
as an isolated factor does not ensure an effective imple-
mentation. The presence of remuneration for provision 
of services has been described as an essential factor in 
the implementation process.31 Therefore, in its absence, 
the implementation of the MRF service may be consid-
ered challenging. Lack of remuneration of the service, 
due to the economic nature of the community pharmacy, 
could have had a decisive influence on the progress of 
implementation; however, the magnitude of this effect is 
unknown.
Community pharmacist providers self- reported a high 
fidelity to the service, that is, they reported delivering 
the service according to how it was protocolised. The 
outcome indicators in the comparison of the impact 
study versus the implementation programme provide 
additional face validity to these self- reports. The major 
problem reported in many impact studies is the hetero-
geneity of the intervention; however, in this programme 
the process and dose of the intervention appear to be 
uniform. It is important for usual practice to achieve high 
quality and have a uniform and standardised service to 
the target population. Fidelity scores can be used at the 
level of the individual pharmacy service provider to rein-
force those weakest or most difficult areas for the phar-
macist during the delivery of the service. It can be used as 
a surrogate indicator of the quality and appropriateness 
of the educators, pedagogy and content of the training 
programme in the preparation stage. The work of PCFs 
can also be assessed using this fidelity measure.
The extent of integration of the service throughout the 
programme seemed appropriate with mean scores of about 
Table 3 Baseline characteristics of the sample: impact study and implementation programme (6 and 12 months)
Baseline for patients completing 6 months








P valueMean SD Mean SD Mean SD
Age (years) 75.3 6.5 75.4 6.4 0.978 73.4 5.7 ≤0.05
Gender (female), n (%) 409 60.1 517 59.2 0.718 99 56.9 0.448
Number of medications 7.74 2.5 9.05 3.0 <0.001 9.38 3.1 <0.001
Number of health problems 4.96 1.8 5.98 2.0 <0.001 6.08 2.2 <0.001
Non- controlled health problems 1.46 1.3 1.39 1.4 0.351 1.57 1.5 0.159
Percentage of non- controlled health 
problems (%)
29.4 23.2 NA 25.8 NA
Quality of life related to health 64.97 18.6 64.53 19.2 0.676 63.6 19.6 0.389
NA, not applicable.









P valueMean SD Mean SD Mean SD Mean SD Mean SD
Impact study (n=688) 7.74 2.5 7.45 2.4 −0.29 1.3 ≤0.05 NA NA NA
Implementation programme (n=608) 9.05 3.0 8.99 3.1 −0.06 1.6 NS NA NA NA
Implementation programme (n=176) 9.38 3.1 9.23 3.2 −0.15 1.2 NS 8.99 3.4 0.39 2.3 ≤0.05
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4 out of 5 in a Likert- type scale. It should be noted that 
the dimension that obtained the lowest score was related 
to the continuous evaluation of the service within each 
participating pharmacy, with an average score of 2.99 (SD: 
0.11), reflecting that in current practice practitioners are 
not accustomed to evaluating their practice. The routinisa-
tion of the service, with an average score of 3.07 (SD: 0.99), 
also indicated some difficulties in adopting new practices. 
These results may be related again to the absence in current 
practice of a portfolio of services that would constitute an 
essential part of the daily activity of community pharmacy. 
However, improvements in the training programmes should 
be considered in any future implementation programme. 
Nevertheless, these results provide some evidence that it 
is possible to integrate the MRF service on a large scale to 
usual practice in Spain.
The evaluation of the clinical, economic and human-
istic effectiveness of this MRF service innovation was the 
main objective of the first phase of the research. However, 
a critical point of any implementation process and/or 
programme32 is to ensure that any potential adaptation for 
the generalisation of the service to the pharmacy popula-
tion does not significantly diminish the previously identified 
patient and system benefits.15 26 28 One of the major innova-
tions and added value of our implementation programme 
was evaluating these clinical and humanistic benefits. 
Interestingly, patients recruited during the implementa-
tion programme were more complex, that is, with higher 
statistically significant baseline number of medications and 
percentage of uncontrolled health problems. The patients 
followed up for 12 months were also more complex. The 
probable reason is that pharmacists are identifying higher 
risk patients for the longer follow- up period and/or these 
patients are remaining longer in the programme. Despite 
this issue the results obtained with the implementation 
programme follow the same trend as those in the impact 
study, a positive impact on the clinical and humanistic 
outcomes both at 6 and 12 months of providing the service. 
However, the magnitude of the outcomes is delayed. Most 
outcomes at 6 months of the impact study show a slightly 
higher effect than those at 6 months of the implementation 
programme. For example, the decline in emergency visits 
in the impact study and implementation programme was 
reduced by 53.4% and 43.0%, respectively. At 12 months 
of the implementation programme the percentage of visits 
had been reduced by 56.8%. A similar trend can be seen 










Mean SD Mean SD Mean SD Mean SD Mean SD
Impact study 
(n=688)








1.57 1.5 NA NA NA NA 0.75 1 −0.82 1.4 −52.20 ≤0.05
*Baseline data are the number of non- controlled health problems at the initiation of the study.
NA, not available.
Table 6 Emergency visits: impact study (6 months) and implementation programme (6 and 12 months)
Baseline 6 months Percentage 
change P value
Between 6 and 
12 months Percentage 
change P valuen % n % n %
Impact study* (n=667) 193 28.9 90 14.7 −53.40 ≤0.05 NA NA NA
Implementation programme† 
(n=575)
121 20.2 69 12 −43.00 ≤0.05 NA NA NA
Implementation programme‡ 
(n=160)
44 25.4 NA NA NA 19 11.9 −56.80 ≤0.05
*Impact study baseline is the number of emergency department visits in the 6- month period prior to the study, and from baseline to 6 months 
are the emergency department visits during the 6 months of the study.
†Implementation programme (6 months) baseline is the number of emergency department visits in the 6 months prior to the study. The 
6- month period is from baseline to 6 months.
‡Implementation programme (12 months) baseline is the number of emergency department visits during the first 6 months prior to the study. 
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in the reduction in the number of medications, in the 
impact study at 6 months by 0.29, and in the implementa-
tion programme at 6 months by 0.06 and at 12 months by 
0.39. These results obtained at 12 months of MRF are very 
similar to the findings of Jódar- Sánchez et al.33 In their study 
of 12 months, the MRF service was delivered to patients 65 
years of age or older institutionalised in geriatric residences 
in the autonomous community of Andalucía. It achieved 
a statistically significant decrease of 0.47 (p≤0.001) in the 
average number of medications. Other studies confirm 
these findings.34–37 Despite this decline in medications, the 
impact study reported a decline in the number of uncon-
trolled health problems of 57% at 6 months and the imple-
mentation programme of 52% at 12 months.
One of the more interesting effects is the number of 
uncontrolled health problems of patients at baseline. It 
would be logically assumed that since these are polymedi-
cated patients their chronic diseases should be adequately 
managed. However, it is evident that this is not the case 
since both the impact study and the implementation 
programme at baseline report polypharmacy with limited 
therapeutic results, reinforcing the need to implement 
services such as MRF.
Limitations
There were various limitations to this study, in particular 
the self- reporting nature of some variables for patients 
and pharmacists. The number of reported hospital admis-
sions was verified with hospital records for the impact 
study but not for the implementation study. To ensure 
comparativeness, the raw data for both studies have 
been reported in this paper. For the impact study, the 
data published by Jódar- Sánchez et al15 for the reported 
number of hospitalisations excluded any prescheduled 
hospitalisations. However, in the Malet- Larrea et al the 
association of the number of hospitalisations with drug- 
related problems as ascertained by a panel of medical 
internists was reported. Due to the unavailability of the 
causes of emergency visits, it was not possible to link them 
to Drug Related Problems (DRP) in both studies. The 
determination of controlled or not controlled health 
problems, in a small number of cases, where objective 
clinical data were unavailable, was dependent on the 
clinical judgement of the pharmacist. The fidelity of the 
intervention was, for practical reasons, only episodically 
observed by the PCFs.
Table 7 Hospitalisations: impact study (6 months) and implementation programme (6 and 12 months)
Previous 6 
months 6 months Percentage 
change P value
Between 6 and 
12 months n (%) Percentage 
change P valuen % n % n %
Impact study* (n=663 baseline, 
n=613 at 6 months)
89 13.4 36 5.9 −59.6 ≤0.05 NA NA NA
Implementation programme† 
(n=594 baseline, n=570 at 6 
months)
64 10.8 41 7.2 −35.9 ≤0.05 NA NA NA
Implementation programme‡ 
(n=170 at 6 months basal, n=154 
at 12 months)
19 11.2 NA NA NA 7 4.5 −63.2 ≤0.05
*Impact study baseline is the number of hospitalisations in the 6- month period prior to the study. The 6- month period is from baseline to 6 
months.
†Implementation programme (6 months) baseline is the number of hospitalisation visits in the 6 months prior to the study. The 6- month period 
is from baseline to 6 months.
‡Implementation programme (12 months) baseline is the number of hospitalisations visits during the first 6 months prior to the study. The 12 
months is the number of hospitalisation visits during the 6–12 months of the programme.
NA, not available.








P valueHRQL SD HRQL SD % SD HRQL SD % SD
Impact study (n=688) 64.97 18.5 70.48 17.1 5.51 15.3 ≤0.05 NA NA NA
Implementation programme 
(n=597)
64.53 19.2 67.42 18.6 2.89 17 ≤0.05 NA NA NA
Implementation programme 
(n=170)
63.1 19.5 NA NA NA 69.84 17.2 6.74 18.7 ≤0.05
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CONCLUSION
The approach taken in this study allowed for the analysis 
of the effectiveness of the implementation programme in a 
holistic way, with the aim of identifying areas for improve-
ment, including the training provided at different levels 
and the length of the final scaling- up programme to the 
target population. The resource allocation and the closer 
monitorisation during a cluster randomised trial than 
during an implementation programme may account for 
the delay in achieving clinical and humanistic benefits. The 
implementation of professional pharmaceutical services is a 
complex multifactorial process, conditioned by numerous 
implementation factors at different levels. What appears 
evident is that in the absence of remuneration, the imple-
mentation of the MRF service is a slow process, taking at 
least a minimum of 12 months. Without remuneration its 
long- term sustainability can also be questioned. The use of 
a structured, multilevel, theory- based approach permitted 
a practical and rigorous assessment of the programme in a 
holistic manner, providing areas for improvements in the 
future.
The evidence provided in this comparative study 
should encourage policy makers to allocate resources to 
the healthcare system to adopt MRF with an implementa-
tion programme due to the high morbidity of an elderly 
population with multiple chronic diseases, which is 
increasingly challenging the sustainability of most coun-
tries’ healthcare systems.
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